Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (19)

2024

  1. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

    Clinical Cancer Research, Vol. 30, Núm. 6, pp. 1093-1103

2022

  1. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations

    JAMA Oncology, Vol. 8, Núm. 11, pp. 1668-1675

  2. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052

2021

  1. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

    Cancer Treatment Reviews, Vol. 83

  2. Phase Ib dose-escalation/expansion trial of ribociclib in combination with everolimus and exemestane in postmenopausal women with HR+, HER2- advanced breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 24, pp. 6417-6428

2019

  1. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

    Future Oncology, Vol. 15, Núm. 19, pp. 2211-2225

2017

  1. The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group

    npj Breast Cancer, Vol. 3, Núm. 1

  2. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies

    Cancer Treatment Reviews, Vol. 61, pp. 53-60

2016

  1. HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?

    Oncology (Switzerland), Vol. 89, Núm. 2, pp. 79-87

  2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

    Oncotarget, Vol. 6, Núm. 35, pp. 37269-37280

  3. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Nature Genetics, Vol. 47, Núm. 3, pp. 250-256

2014

  1. HER2 testing: Current status and future directions

    Cancer Treatment Reviews, Vol. 40, Núm. 2, pp. 276-284

  2. Survival of women with inflammatory breast cancer: A large population-based study

    Annals of Oncology, Vol. 25, Núm. 6, pp. 1143-1151

2013

  1. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study

    Oncologist, Vol. 18, Núm. 3, pp. 257-264

  2. Handbook of HER2-targeted agents in breast cancer

    Springer Healthcare, pp. 1-96

2012

  1. Progress against solid tumors in danger: The metastatic breast cancer example

    Journal of Clinical Oncology